Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU and US differ over regulation of plano contact lenses:

This article was originally published in Clinica

Executive Summary

Plano (non-prescription) decorative contact lenses are not regulated as medical devices in the EU because the Medical Devices Directive (MDD) explicitly covers devices "intended to be mainly for a medical purpose". That was the response by the European Commission to a written question raised by UK MEP Glenis Willmott, who wanted to know why such lenses were not classified as medical devices in the EU, when they are in the US. "Both corrective and non-corrective lenses have the same potential health risks and effects on the eye if improperly manufactured or used without the consultation and supervision of an eye practitioner," she observed. The Commission emphasises that products intended to have a merely aesthetic purpose are not medical devices and that this is made clear in the EU guidance document, Meddev 2.1. The Commission does not offer in its response any clarification as to how plano lenses might be regulated.

You may also be interested in...



Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel